NPC Archive Item: Rosuvastatin has no CV benefits in patients undergoing haemodialysis

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 6th April 2009 The AURORA study found rosuvastatin had no cardiovascular mortality or morbidity benefits in patients with end-stage renal disease undergoing haemodialysis. Action Patients with chronic kidney disease […]

NPC Archive Item: MeReC Bulletin on lipid modification now published

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. This MeReC Bulletin summarises the NICE guidance on lipid modification and addresses some important supplementary clinical questions. The most recent MeReC Bulletin: Lipid-modifying treatment (Vol. 19, No. 3) is […]

NPC Archive Item: Is lower cholesterol better? – the SEARCH continues

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. Early results of the SEARCH study have been presented at the American Heart Association conference and as such have not yet been fully evaluated. They suggest no statistically significant […]

NPC Archive Item: Omega-3 polyunsaturated fatty acids, but not rosuvastatin, may provide a benefit in heart failure

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. GISSI-HF investigators. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet (early online publication) 31 August 2008; […]

NPC Archive Item: NICE highlights NPC patient decision aid in its lipid guidance

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. NICE Clinical Guideline 67: Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease Patients should be given information about their […]

NPC Archive Item: NICE publishes guidance on CV risk assessment and lipid modification

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. NICE Clinical Guideline 67: Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease NICE recommends using simvastatin 40 mg as […]

NPC Archive Item: Ezetimibe▼ doesn’t ENHANCE statins

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. What is this about? The results (login required) of the ENHANCE Study have found no significant difference between the combination of ezetimibe▼ and simvastatin compared to simvastatin alone in […]